Showing 6-10 of 61 :
Artificial Intelligence: Friend or Foe?

Dermatology Times October 3, 2023 Read the full article >> Artificial intelligence (AI) has been a buzzword in health care for some time, but do clinicians, especially in dermatology, view it as friend or foe? Applications and use of AI in dermatology are comparatively new and have focused primarily on the relatively narrow application of[…]

OM1 Launches Asthma and Chronic Rhinosinusitis Datasets to Expand Real-World Evidence in Respiratory and ENT

Business Wire October 2, 2023 Read the full press release >> BOSTON–(BUSINESS WIRE)–OM1, a leading real-world data, AI, and technology company with a focus on chronic diseases, announced the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma. Both datasets are derived from longitudinal follow-up of patients seen by specialists and focus on patient characteristics, symptoms,[…]

OM1 Launches Hidradenitis Suppurativa Dataset to Expand Real-World Evidence in Dermatology

Business Wire September 21, 2023 Read the full release >> BOSTON–(BUSINESS WIRE)–OM1 a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the continued expansion of its Dermatology Network to include Hidradenitis Suppurativa (HS), a systemic inflammatory disease, enhancing the dataset with almost 26,000 patient records. Studies continue to show the link between[…]

Leveraging Real-World Data for Precision Obesity Treatment

Listen to the full podcast >> Healtheconmoncs.com July 26, 2023 On this episode of tHEORetically speaking features Gary Curhan, Chief Medical Officer and Jessica Paulus, Vice President of Research at OM1, as they answer questions on Leveraging Real-World Data for Precision Obesity Treatment.

OM1 Launches Parkinson’s Disease Premium Dataset to Expand Real-World Evidence in Neuroscience

Read the full press release >> BOSTON–(BUSINESS WIRE)–OM1, the leading real-world data and technology company focused on chronic conditions, today announced the launch of its Parkinson’s Disease (PD) premium dataset and the enhancement of its Mental Health & Neuroscience Real-World Data Network. The dataset includes more than 7,000 patients prospectively followed by neurologists in hundreds of clinics across[…]